Filtered By:
Condition: Cholesterol
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 572 results found since Jan 2013.
Inflammatory gene silencing in activated monocytes by a cholesterol tagged-miRNA/siRNA: a novel approach to ameliorate diabetes induced inflammation
AbstractThere is a major unmet need for the development of effective therapies for diabetes induced inflammation. Increased adenosine-uridine rich elements (AREs) containing mRNAs of inflammatory molecules are reported in inflamed monocytes. Destabilizing these inflammatory mRNAs by the miR-16 could reduce inflammation. DNA microarrays and in vitro cell studies showed that exogenous miR16 and its mimic treatment, in LPS/PMA induced monocytes, significantly downregulated several ARE containing inflammatory cytokine mRNAs similar to those seen in the normal monocytes. Ingenuity pathway analyses showed exogenous miR-16 or ...
Source: Cell and Tissue Research - May 23, 2022 Category: Cytology Source Type: research
SiRNA Transfection with Cholesterol Modification from Electrospun PET Facilitates Gene Silencing in Human Aortic Smooth Muscle Cells
Anastomotic intimal hyperplasia (AIH) remains the leading cause for prosthetic arterial graft failure. RNAi is a promising tool to silence genes such as Thrombospondin-2 (TSP-2), previously shown by our group to be upregulated in AIH. The present study is aimed at delivering modified TSP-2 siRNA (3’cholesterol tagged TSP-2 siRNA) from electrospun polyethylene terephthalate (ePET) and therefore knocking down TSP-2 gene and ultimately inhibiting AIH.
Source: Journal of Surgical Research - January 10, 2013 Category: Surgery Authors: M.C. Chun, H.S. Oliver-Allen, C.S. Nabzdyk, S.G. Pathan, M.D. Phaneuf, L. Pradhan-Nabzdyk, F.W. LoGerfo Source Type: research
SiRNA Transfection With Cholesterol Modification From Electrospun PET Facilitates Gene Silencing in Human Aortic Smooth Muscle Cells
Anastomotic intimal hyperplasia (AIH) remains the leading cause for prosthetic arterial graft failure. RNAi is a promising tool to silence genes such as Thrombospondin-2 (TSP-2), previously shown by our group to be upregulated in AIH. The present study is aimed at delivering modified TSP-2 siRNA (3’cholesterol tagged TSP-2 siRNA) from electrospun polyethylene terephthalate (ePET) and therefore knocking down TSP-2 gene and ultimately inhibiting AIH.
Source: Journal of Surgical Research - January 10, 2013 Category: Surgery Authors: M.C. Chun, H.S. Oliver-Allen, C.S. Nabzdyk, S.G. Pathan, M.D. Phaneuf, L. Pradhan-Nabzdyk, F.W. LoGerfo Tags: Oral Session: Thursday 2/7 7:30 AM to 9:30 AM Source Type: research
Cationic cholesterol-modified gelatin as an in vitro siRNA delivery vehicle
Mol. BioSyst., 2013, Advance ArticleDOI: 10.1039/C2MB25424G, CommunicationPallavi Ananda Kadengodlu, Toshiro Aigaki, Hiroshi Abe, Yoshihiro ItoPolymeric micelle prepared through the self-assembly of cationic cholesterol-modified gelatin (cCMG) was tested for siRNA delivery. It exerted the desired effect of gene knockdown in HeLa cells stably expressing the luciferase gene and achieved two-fold increase in the knockdown ability when compared to Lipofectamine[registered sign] 2000. cCMG exhibited excellent stability and increased the biological stability of the siRNA in serum.To cite this article before page numbers are assi...
Source: RSC - Mol. BioSyst. latest articles - January 12, 2013 Category: Molecular Biology Authors: Pallavi Ananda Kadengodlu Source Type: research
VE-statin/Egfl7 siRNA inhibits angiogenesis in malignant glioma in vitro.
This study investigated the role of VE-statin/Egfl7 and its mechanism in angiogenesis in malignant glioma. Transwell culture plates were used to establish an U251-HUVEC co-culture system, which was used to mimic the interaction between malignant glioma and endothelial cells. Lentiviral vectors expressing VE-statin/Egfl7 siRNA were constructed, and U251 cells and HUVECs were transfected to inhibit VE-statin/Egfl7 expression. The proliferation, adherence, migration, and lumen formation of endothelial cells were assayed to investigate the influence of VE-statin/Egfl7 on angiogenesis in malignant glioma in vitro. Data showed t...
Source: International Journal of Clinical and Experimental Pathology - April 7, 2014 Category: Pathology Authors: Huang C, Yuan X, Li Z, Tian Z, Zhan X, Zhang J, Li X Tags: Int J Clin Exp Pathol Source Type: research
Identification of siRNA delivery enhancers by a chemical library screen
This study suggests that a pharmacological approach can improve the delivery of siRNAs in a system-specific fashion, by exploiting distinct mechanisms and acting upon multiple cell types.
Source: Nucleic Acids Research - September 18, 2015 Category: Research Authors: Gilleron, J., Paramasivam, P., Zeigerer, A., Querbes, W., Marsico, G., Andree, C., Seifert, S., Amaya, P., Stoter, M., Koteliansky, V., Waldmann, H., Fitzgerald, K., Kalaidzidis, Y., Akinc, A., Maier, M. A., Manoharan, M., Bickle, M., Zerial, M. Tags: Molecular Biology Source Type: research
Development of a Peptide-Modified siRNA Nanocomplex for Hepatic Stellate Cells
Insulin-like growth factor 2 receptor (IGF2R) is overexpressed in activated Hepatic stellate cells (HSCs) and therefore can be utilized for HSC-specific drug delivery. We recently discovered an IGF2R-specific peptide using a novel biopanning. Here, we adopted biotin-conjugated IGF2R-specific peptide, cholesterol, and vitamin A as the targeting ligands for the neutravidin-based siRNA nanocomplex to deliver PCBP2 siRNA, a potentially antifibrotic agent, to HSCs. Compared to Vitamin A and cholesterol, the IGF2R-specific peptide exhibited the highest targeting effect to human LX-2 HSC, rat HSC-T6 cell line, and activated primary rat HSCs.
Source: Nanomedicine : Nanotechnology, Biology, and Medicine - September 7, 2017 Category: Nanotechnology Authors: Zhen Zhao, Yuanke Li, Akshay Jain, Zhijin Chen, Hao Liu, Wei Jin, Kun Cheng Source Type: research
GSE93608 Comparison of HBO1 siRNA-treated Human Umbilical Vein Endothelial Cells (HUVECs) and control siRNA-treated HUVECs
Contributors : Philip A Marsden ; Matthew S YanSeries Type : Expression profiling by array ; Non-coding RNA profiling by arrayOrganism : Homo sapiensTo determine the role of HBO1 in EC physiology, gene expression analysis was conducted on control and HBO1 siRNA-treated HUVECs. A total of 263 differentially regulated protein-coding transcripts were detected, many of which are key for growth and angiogenesis. Additionally, many genes involved in cell cycle, cell division, and DNA replication were dysregulated. HBO1-regulated genes were verified by qRT-PCR, including those with roles in vessel tone regulation (e.g. ACE1), ves...
Source: GEO: Gene Expression Omnibus - January 19, 2018 Category: Genetics & Stem Cells Tags: Expression profiling by array Non-coding RNA profiling by array Homo sapiens Source Type: research
Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
AbstractPurpose of ReviewThe aim of low-density lipoprotein-cholesterol (LDL-C) lowering therapies is to safely achieve a consistent and long-term reduction in exposure of the vasculature to atherogenic lipoproteins in order to reduce the risk of atherosclerotic cardiovascular (CV) disease and the associated CV events, such as myocardial infarctions and ischemic strokes. This review summarizes the concept and clinical development of a novel molecular approach to efficiently lower LDL-C, a synthetic small interfering ribonucleic acid (siRNA) —inclisiran—directed against proprotein convertase subtilisin-kexin type 9 (PCS...
Source: Current Cardiology Reports - October 21, 2020 Category: Cardiology Source Type: research
Injectable siRNA Approved for Lowering Cholesterol
The FDA has approved an injectable small interfering ribonucleic acid (siRNA) therapy for lowering low-density lipoprotein (LDL-C) in certain adults. It is the first siRNA in its class and one of the first developed for a nonorphan indication.
Source: JAMA - March 1, 2022 Category: General Medicine Source Type: research
Lipid nanoparticle delivery of siRNA targeting < em > Cyp2e1 < /em > gene attenuates subacute alcoholic liver injury in mice
CONCLUSIONS: The si-Cyp2e1 LNP may attenuate subacute alcoholic liver injury in mice mainly by reducing reactive oxygen levels, increasing antioxidant activity, blocking oxidative stress pathways and reducing ethanol-induced steatosis and inflammation.PMID:37476942 | DOI:10.3724/zdxbyxb-2022-0729
Source: Cancer Control - July 21, 2023 Category: Cancer & Oncology Authors: Shuang Wu Qiubing Chen Yalan Wang Hao Yin Yuan Wei Source Type: research
GSE241894 Comparison of biochemical pathways affected by treatment with 4-methylumbelliferone and siRNA mediated knock down reveals hyaluronan synthase type 2 as a key pharmacological target in liver fibrosis
Contributors : Noreen Halimani ; Mikhail Nesterchuk ; Alexandra A Tsitrina ; Marat Sabirov ; Irina N Andreichenko ; Nataliya O Dashenkova ; Alexey M Kulikov ; Timofei S Zatsepin ; Roman A Romanov ; Arsen S Mikaelyan ; Yuri V KotelevtsevSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusHepatic fibrosis is a morbid pathology with unmet medical need. 4- methylumbelliferone (4-MU), an inhibitor of hyaluronan (HA) synthesis was shown to be safe in phase one clinical trials. To support drug development, it is essential to decipher 4-MU ’s pharmacological targets. Here, we compared the effec...
Source: GEO: Gene Expression Omnibus - August 31, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor
In this study, LNP-DP1 –a cationic lipid nanoparticle formulation –is reported as a vehicle to restore deregulated gene expression in hepatic carcinoma cells by siRNA and miRNA delivery using a mouse model. Further expansions to this study may enable transition to clinical trials of this system.Graphical Abstract: The schematic representation of mi-/si-RNA encapsulated by PEG modified LNP-DP1 which is mainly composed of EggPC, cholesterol and cationic lipid DODMA. The LNP-DP1 (red particles) can be specifically and efficiently taken up by hepatocytes and tumor cells (blue nuclei and green cell outline) after delivery t...
Source: Nanomedicine : Nanotechnology, Biology, and Medicine - June 3, 2013 Category: Nanotechnology Authors: Shu-hao Hsu, Bo Yu, Xinmei Wang, Yuanzhi Lu, Carl R. Schmidt, Robert J. Lee, L. James Lee, Samson T. Jacob, Kalpana Ghoshal Tags: Genetics, Gene Delivery, HEP-CC, Micro-RNA Delivery, Cationic Lipid NPs Source Type: research
Visualization of self-delivering hydrophobically modified siRNA cellular internalization
siRNAs are a new class of therapeutic modalities with promising clinical efficacy that requires modification or formulation for delivery to the tissue and cell of interest. Conjugation of siRNAs to lipophilic groups supports efficient cellular uptake by a mechanism that is not well characterized. Here we study the mechanism of internalization of asymmetric, chemically stabilized, cholesterol-modified siRNAs (sd-rxRNAs®) that efficiently enter cells and tissues without the need for formulation. We demonstrate that uptake is rapid with significant membrane association within minutes of exposure followed by the formation ...
Source: Nucleic Acids Research - January 8, 2017 Category: Research Authors: Ly, S., Navaroli, D. M., Didiot, M.-C., Cardia, J., Pandarinathan, L., Alterman, J. F., Fogarty, K., Standley, C., Lifshitz, L. M., Bellve, K. D., Prot, M., Echeverria, D., Corvera, S., Khvorova, A. Tags: Chemical Biology and Nucleic Acid Chemistry Source Type: research
Dyslipidaemia: Promising results with siRNA against PCSK9
Nature Reviews Cardiology 14, 252 (2017).
doi:10.1038/nrcardio.2017.43
Author: Irene Fernández-Ruiz
Two single injections of inclisiran, a small interfering RNA (siRNA) that targets PCSK9 mRNA, induce a 50% reduction in LDL-cholesterol (LDL-C) levels in 6 months, according to findings from the phase II ORION-1 trial presented at ACC.17. A total of 501 patients at high
Source: Nature Reviews Cardiology - March 31, 2017 Category: Cardiology Authors: Irene Fern ández-Ruiz Tags: Research Highlight Source Type: research
